Advertisement

Applied Health Economics and Health Policy

, Volume 17, Issue 1, pp 111–121 | Cite as

The Economic Burden of Chronic Obstructive Pulmonary Disease in Greece

  • Georgia KourlabaEmail author
  • Georgios Hillas
  • Theodoros Vassilakopoulos
  • Nikos Maniadakis
Original Research Article

Abstract

Background

Chronic obstructive pulmonary disease (COPD) is a leading cause of disability and death worldwide, imposing a substantial socioeconomic burden on societies and patients due to the long-term management required.

Objective

To assess the economic burden of COPD in Greece and its potential determinants.

Methods

A population-based, random-digit dialled, telephone nationwide survey was conducted to recruit patients with COPD in Greece (N = 351). A structured questionnaire was used to collect data. The total annual cost per patient from a societal perspective was calculated.

Results

The mean (95% CI) annual total cost per patient for the management of COPD from a societal perspective was €2150 (€1879–€2443). The total annual cost was mainly driven by the medication cost (36.1%), followed by the cost of hospitalizations (26.7%) and long-term oxygen therapy (13.8%). Multiple generalized linear model revealed that age, COPD Assessment Test (CAT) score and exacerbations were independently associated with the total annual cost.

Conclusion

Investment in interventions aiming at delaying progression of disease, preventing acute exacerbations, and managing chronic symptoms are required to reduce the overall economic burden of COPD in Greece.

Notes

Author Contributions

GK designed the study, conducted the analyses, interpreted the results, and wrote the manuscript. NM, GH, and TV contributed to questionnaire development, results interpretation, and manuscript writing.

Compliance with Ethical Standards

Data availability statement

The dataset along with the software code will be provided upon request.

Conflict of interest

The authors Georgia Kourlaba, Georgios Hillas, Theodoros Vassilakopoulos, and Nikos Maniadakis declare that they have no conflicts of interest.

Funding

This study was funded by the Hellenic Thoracic Society.

Ethical approval

According to the Greek legislation (Law 2328/1995, Presidential Decree 310/1996, Law 3603/2007, Law 2472/1997, Law 3471/2006) there is no need for ethical approval for telephone surveys such the one presented here (Association of Opinion Polls and Survey Organisations—http://www.sedea.gr).

Informed consent

Verbal informed consent was obtained from all individual participants included in the study.

Supplementary material

40258_2018_431_MOESM1_ESM.pdf (705 kb)
Supplementary material 1 (PDF 705 kb)

References

  1. 1.
    Soriano JB, Rodriguez-Roisin R. Chronic obstructive pulmonary disease overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac Soc. 2011;8(4):363–7.CrossRefGoogle Scholar
  2. 2.
    Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137–48.CrossRefGoogle Scholar
  3. 3.
    Wouters EF. Economic analysis of the confronting COPD survey: an overview of results. Respir Med. 2003;97 Suppl C:S3–14.CrossRefGoogle Scholar
  4. 4.
    Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health. 2011;11:612.CrossRefGoogle Scholar
  5. 5.
    Detournay B, Pribil C, Fournier M, Housset B, Huchon G, Huas D, et al. The SCOPE study: health-care consumption related to patients with chronic obstructive pulmonary disease in France. Value Health. 2004;7(2):168–74.CrossRefGoogle Scholar
  6. 6.
    Foster TS, Miller JD, Marton JP, Caloyeras JP, Russell MW, Menzin J. Assessment of the economic burden of COPD in the US: a review and synthesis of the literature. COPD. 2006;3(4):211–8.CrossRefGoogle Scholar
  7. 7.
    Menzin J, Boulanger L, Marton J, Guadagno L, Dastani H, Dirani R, et al. The economic burden of chronic obstructive pulmonary disease (COPD) in a US Medicare population. Respir Med. 2008;102(9):1248–56.CrossRefGoogle Scholar
  8. 8.
    Polatli M, Ben Kheder A, Wali S, Javed A, Khattab A, Mahboub B, et al. Chronic obstructive pulmonary disease and associated healthcare resource consumption in the Middle East and North Africa: the BREATHE study. Respir Med. 2012;106(Suppl 2):S75–85.CrossRefGoogle Scholar
  9. 9.
    Kourlaba G, Hillas G, Vassilakopoulos T, Maniadakis N. The disease burden of chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2016 (in press).Google Scholar
  10. 10.
    Geitona M, Hatzikou M, Steiropoulos P, Alexopoulos EC, Bouros D. The cost of COPD exacerbations: a university hospital–based study in Greece. Respir Med. 2011;105(3):402–9.CrossRefGoogle Scholar
  11. 11.
    Souliotis K, Kousoulakou H, Hillas G, Tzanakis N, Toumbis M, Vassilakopoulos T. The direct and indirect costs of managing chronic obstructive pulmonary disease in Greece. Int J Chron Obstruct Pulmon Dis. 2017;12:1395–400.CrossRefGoogle Scholar
  12. 12.
    Stafyla E, Geitona M, Kerenidi T, Economou A, Daniil Z, Gourgoulianis KI. The annual direct costs of stable COPD in Greece. Int J Chron Obstruct Pulmon Dis. 2018;13:309–15.CrossRefGoogle Scholar
  13. 13.
    Landis SH, Muellerova H, Mannino DM, Menezes AM, Han MK, van der Molen T, et al. Continuing to confront COPD international patient survey: methods, COPD prevalence, and disease burden in 2012–2013. Int J Chron Obstruct Pulmon Dis. 2014;9:597–611.Google Scholar
  14. 14.
    Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–54.CrossRefGoogle Scholar
  15. 15.
    Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, et al. Properties of the COPD assessment test in a cross-sectional European study. Eur Respir J. 2011;38(1):29–35.CrossRefGoogle Scholar
  16. 16.
    Uzaslan E, Mahboub B, Beji M, Nejjari C, Tageldin MA, Khan JA, et al. The burden of chronic obstructive pulmonary disease in the Middle East and North Africa: results of the BREATHE study. Respir Med. 2012;106(Suppl 2):S45–59.CrossRefGoogle Scholar
  17. 17.
    Greek Ministry of Health M. Drug price bulletin. 2015.Google Scholar
  18. 18.
    International Monetary Fund. World Economic Outlook Database. 2013. http://www.imf.org/external/pubs/ft/weo/2012/02/weodata/index.aspx.
  19. 19.
  20. 20.
    Jonsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357–9.CrossRefGoogle Scholar
  21. 21.
    Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19(23):3219–36.CrossRefGoogle Scholar
  22. 22.
    Moran JL, Solomon PJ, Peisach AR, Martin J. New models for old questions: generalized linear models for cost prediction. J Eval Clin Pract. 2007;13(3):381–9.CrossRefGoogle Scholar
  23. 23.
    Kamusheva M, Dimitrova M, van Boven JF, Postma MJ, van der Molen T, Kocks JW, et al. Clinical characteristics, treatment patterns, and socio-economic burden of COPD in Bulgaria. J Med Econ. 2017;20(5):503–9.CrossRefGoogle Scholar
  24. 24.
    de Miguel Diez J, Carrasco Garrido P, Garcia Carballo M, Gil de Miguel A, Rejas Gutierrez J, Bellon Cano JM, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4):701–12.CrossRefGoogle Scholar
  25. 25.
    Dal Negro RW, Tognella S, Tosatto R, Dionisi M, Turco P, Donner CF. Costs of chronic obstructive pulmonary disease (COPD) in Italy: the SIRIO study (social impact of respiratory integrated outcomes). Respir Med. 2008;102(1):92–101.CrossRefGoogle Scholar
  26. 26.
    Kim J, Lee TJ, Kim S, Lee E. The economic burden of chronic obstructive pulmonary disease from 2004 to 2013. J Med Econ. 2015;2015:1–8.Google Scholar
  27. 27.
    Khakban A, Sin DD, FitzGerald JM, Ng R, Zafari Z, McManus B, et al. Ten-year trends in direct costs of COPD: a population-based study. Chest. 2015;148(3):640–6.CrossRefGoogle Scholar
  28. 28.
    Migdalis I, Rombopoulos G, Hatzikou M, Manes C, Kypraios N, Tentolouris N. The cost of managing Type 2 diabetes mellitus in Greece: a retrospective analysis of 10-year patient level data “The HERCULES Study”. Int J Endocrinol. 2015;2015:520759.Google Scholar
  29. 29.
    Maniadakis N, Kourlaba G, Cokkinos DV, Angeli A, Kyriopoulos J. The economic burden of atherothrombosis in Greece: results from the THESIS study. Eur J Health Econ. 2013;14(4):655–65.CrossRefGoogle Scholar
  30. 30.
    Holbrook AL, Green MC, Krosnick JA. Telephone versus face-to-face interviewing of national probability samples with long questionnaires: comparisons of respondent satisficing and social desirability response bias. Public Opinion Q. 2003;67:79–125.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.EVROSTON LPAthensGreece
  2. 2.Department of Critical Care of Evangelismos HospitalMedical School of National and Kapodistrian University of AthensAthensGreece
  3. 3.Department οf Health Services Organization and ManagementNational School οf Public HealthAthensGreece

Personalised recommendations